SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …

Adipose tissue plays essential roles in maintaining lipid and glucose homeostasis. To date
several types of adipose tissue have been identified, namely white, brown, and beige, that …

Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for
treatment of diabetes, have been shown to possess a favorable metabolic profile and to …

RY rheostat, whereas AMPK discerns the balance between ATP and AMP in the cytosol.
Importantly, SIRT1 and AMPK are activated not only by fasting but also by a broad range of …

The cardioprotective effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors may be
related to their ability to induce a fasting-like paradigm, which triggers the activation of …

Sodium glucose co-transporter 2 (SGLT2) inhibitors are effective antihyperglycemic agents
by inhibiting glucose reabsorption in the proximal tubule of the kidney. Besides improving …

Simple Summary Despite significant advances in the treatment of cancer, it remains a major
cause of death worldwide and new treatment options are constantly being sought. An …

BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect
the kidneys and heart, but the underlying mechanism remains poorly understood …

Abstract Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are anti-hyperglycemic agents
that prevent glucose reabsorption in proximal tubular cells. SGLT2i improves renal …